EVALUATED EFFECTIVENESS OF TRANSARTERIAL CHEMOEMBOLIZATION FOR HEPATOCELLULAR CARCINOMA

Nguyễn Công Long1,, Nguyễn Minh Ngọc1
1 Department of Gastroenterology and Hepatology, Bach Mai Hospital

Main Article Content

Abstract

Objectives: We aimed to determine the effect of transarterial chemoembolization for hepatocellular carcinoma. Methods: A total of 71 patients with hepatocellular carcinoma treated with transarterial chemoembolization. Results: The mean age was 60.9 year. The single tumor accounted for 37 (52.1%). The main cause hepatocellular carcinoma was hepatitis B, 62 patients (87.3%). For overall survival rate of the 71 patients who underwent transarterial chemoembolization were 4.104 years. Conclusion: Transarterial chemoembolization treatment can improve overall survival in patients with hepatocellular carcinoma.

Article Details

References

1. Bertuccio, P., et al., Global trends and predictions in hepatocellular carcinoma mortality. J Hepatol, 2017. 67(2): p. 302-309.
2. Llovet, J.M., et al., Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet, 2002. 359(9319): p. 1734-9.
3. Lo, C.M., et al., Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology, 2002. 35(5): p. 1164-71.
4. Trevisani, F., et al., Etiologic factors and clinical presentation of hepatocellular carcinoma. Differences between cirrhotic and noncirrhotic Italian patients. Cancer, 1995. 75(9): p. 2220-32.